Issue link: https://uberflip.scri.com/i/1521062
0529/24SCR019-14/R3 Abstract Presentation Calendar ASCO® 2024 11 Saturday Friday Sunday Monday Tuesday Publication Only SUNDAY, JUNE 2 ND 11:30am - 6:00pm Central Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 11:30am - 1:00pm 12:42 - 12:48pm S406 Oral 2521 Safety and preliminary efficacy of EIK1001 in combination with pembrolizumab in participants with advanced solid tumors. Tolcher A Johnson M, Patel M Developmental Therapeutics— Immunotherapy 1:00 - 4:00pm 3:21 - 3:33pm Hall B1 Oral LBA5 ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small- cell lung cancer (LS-SCLC). Spigel D Spigel D Plenary Session 4:30 - 6:00pm 5:12 - 5:18pm S406 Oral 8015 DeLLphi-301: Tarlatamab phase 2 trial in small cell lung cancer (SCLC)— Efficacy and safety analyzed by presence of brain metastasis. Dingemans AM Johnson M Lung Cancer—Non- Small Cell Local- Regional/Small Cell/ Other Thoracic Cancers MONDAY, JUNE 3 RD 8:00am - 12:00pm Central Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 8:00 - 9:30am 8:12 - 8:18am E450b Oral 6014 Petosemtamab (MCLA-158) with pembrolizumab as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): Phase 2 study Fayette J Perez C, Fontana E, Harandi A Head and Neck Cancer 9:00am - 12:00pm Hall A Poster 11181 Clinical trial participation and end-of- life care among older adults: A multi- center longitudinal observational cohort analysis of 121,717 patients with cancer Subbiah I Subbiah I Quality Care/Health Services Research 9:00am - 12:00pm Hall A Poster 5594 Phase 3 dose selection for selinexor in TP53wt endometrial cancer based on exposure-response analysis. Makker V Coleman R Gynecologic Cancer 9:00am - 12:00pm Hall A Poster 7071 Longitudinal patterns of patient- reported cognitive impairment in patients with non-Hodgkin lymphoma (NHL) treated with chemotherapy: A group-based trajectory analysis of a nationwide community-based cohort. Zhao T Misleh J Hematologic Malignancies— Lymphoma and Chronic Lymphocytic Leukemia 9:00am - 12:00pm Hall A Poster 7528 OPTec: A phase 2 study to evaluate outpatient (OP) step-up administration of teclistamab (Tec), a BCMA-targeting bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Rifkin R Rifkin R, Schade H, Yasenchak C, Xu W Hematologic Malignancies—Plasma Cell Dyscrasia 9:00am - 12:00pm Hall A Poster 6552 Treatment of acute myeloid leukemia with Orca-T. Pantin J (Faramand R presenting) Pantin J Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant